BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38315961)

  • 1. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
    Varey AHR; Li I; El Sharouni MA; Simon J; Dedeilia A; Ch'ng S; Saw RPM; Spillane AJ; Shannon KF; Pennington TE; Rtshiladze M; Stretch JR; Nieweg OE; van Akkooi A; Sullivan RJ; Boland GM; Gershenwald JE; van Diest PJ; Scolyer RA; Long GV; Thompson JF; Lo SN
    J Clin Oncol; 2024 Apr; 42(10):1169-1180. PubMed ID: 38315961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program.
    Tjokrowidjaja A; Browne L; Soudy H
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e280-e288. PubMed ID: 34811927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.
    Lo SN; Ma J; Scolyer RA; Haydu LE; Stretch JR; Saw RPM; Nieweg OE; Shannon KF; Spillane AJ; Ch'ng S; Mann GJ; Gershenwald JE; Thompson JF; Varey AHR
    J Clin Oncol; 2020 Aug; 38(24):2719-2727. PubMed ID: 32530761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor.
    El Sharouni MA; Stodell MD; Ahmed T; Suijkerbuijk KPM; Cust AE; Witkamp AJ; Sigurdsson V; van Diest PJ; Scolyer RA; Thompson JF; van Gils CH; Lo SN
    Ann Oncol; 2021 Mar; 32(3):375-383. PubMed ID: 33253862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort.
    El Sharouni MA; Varey AHR; Witkamp AJ; Ahmed T; Sigurdsson V; van Diest PJ; Scolyer RA; Thompson JF; Lo SN; van Gils CH
    Br J Dermatol; 2021 Aug; 185(2):412-418. PubMed ID: 33657653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
    J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.
    Bajaj S; Donnelly D; Call M; Johannet P; Moran U; Polsky D; Shapiro R; Berman R; Pavlick A; Weber J; Zhong J; Osman I
    J Natl Cancer Inst; 2020 Sep; 112(9):921-928. PubMed ID: 31977051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
    Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
    Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
    Moncrieff MD; Lo SN; Scolyer RA; Heaton MJ; Nobes JP; Snelling AP; Carr MJ; Nessim C; Wade R; Peach AH; Kisyova R; Mason J; Wilson ED; Nolan G; Pritchard Jones R; Johansson I; Olofsson Bagge R; Wright LJ; Patel NG; Sondak VK; Thompson JF; Zager JS
    J Clin Oncol; 2022 Dec; 40(34):3940-3951. PubMed ID: 35849790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
    Larkin J; Weber J; Del Vecchio M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; De la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Long GV; Lobo M; Askelson M; Ascierto PA; Mandalá M
    Eur J Cancer; 2022 Sep; 173():285-296. PubMed ID: 35964471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
    Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
    Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
    Fujisawa Y; Yoshikawa S; Minagawa A; Takenouchi T; Yokota K; Uchi H; Noma N; Nakamura Y; Asai J; Kato J; Fujiwara S; Fukushima S; Uehara J; Hoashi T; Kaji T; Fujimura T; Namikawa K; Yoshioka M; Murata N; Ogata D; Matsuyama K; Hatta N; Shibayama Y; Fujiyama T; Ishikawa M; Yamada D; Kishi A; Nakamura Y; Shimiauchi T; Fujii K; Fujimoto M; Ihn H; Katoh N
    J Dermatol Sci; 2019 May; 94(2):284-289. PubMed ID: 31023613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
    Weber JS; Poretta T; Stwalley BD; Sakkal LA; Du EX; Wang T; Chen Y; Wang Y; Betts KA; Shoushtari AN
    Cancer Immunol Immunother; 2023 Apr; 72(4):945-954. PubMed ID: 36197494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.
    Mulder EEAP; Johansson I; Grünhagen DJ; Tempel D; Rentroia-Pacheco B; Dwarkasing JT; Verver D; Mooyaart AL; van der Veldt AAM; Wakkee M; Nijsten TEC; Verhoef C; Mattsson J; Ny L; Hollestein LM; Olofsson Bagge R
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of the Melanoma Institute Australia Sentinel Node Metastasis Risk Prediction Tool using the National Cancer Database.
    Freeman SC; Paz Munoz E; Latour E; Lim JY; Yu W
    J Am Acad Dermatol; 2023 Nov; 89(5):967-973. PubMed ID: 37454700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
    Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation in an Australian population of the EORTC-DeCOG nomogram predicting recurrence, distant metastasis and overall mortality in melanoma patients with positive sentinel lymph nodes.
    Li AT; Law J; Ch'ng S; Scolyer RA; Thompson JF; Lo SN; Varey AHR
    Eur J Cancer; 2023 Aug; 189():112901. PubMed ID: 37263897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
    Kanaki T; Stang A; Gutzmer R; Zimmer L; Chorti E; Sucker A; Ugurel S; Hadaschik E; Gräger NS; Satzger I; Schadendorf D; Livingstone E
    Eur J Cancer; 2019 Sep; 119():18-29. PubMed ID: 31401470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.